Push the boundaries of healthcare data.
Evolve the way you access, manage and apply patient-centric insights.
The indispensability of RWD to the future of pharma
Last month, new bipartisan legislation was introduced to harness real-world evidence gathered during emergency use authorization to support future approvals of drugs, biologics, and medical devices by the FDA. Real world data proves value, but challenges remain. Learn how to successfully navigate the RWD landscape and accelerate the process of bringing a new brand to market.
Lowering the Stakes of Real World Data Purchases
The process of data selection and purchasing for anonymous patient longitudinal data (APLD) is rife with inefficiencies and challenges. We regularly hear from pharmaceutical customers about the frustration of managing multiple data vendors to acquire broad and diverse healthcare data to drive commercial, RWE, outcomes, and clinically-focused analytics. The standard way of acquiring this data is a time consuming and costly aspect of doing business. We knew there had to be a better way.